

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

ZJ

中基長壽科學

ZHONG JI LONGEVITY SCIENCE

Zhong Ji Longevity Science Group Limited

中基長壽科學集團有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 767)

**VOLUNTARY ANNOUNCEMENT
SINGAPORE SALES AGENCY CONTRACT**

This announcement is made by Zhong Ji Longevity Science Group Limited (the “**Company**”) on a voluntary basis.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on 9 September 2021 (after trading hours), Blooming Faith Development Limited (“**Blooming Faith**”), a wholly-owned subsidiary of the Company, entered into a sales agency contract (the “**Agency Contract**”) with Vivo Miracle Biotechnology Limited (“**Vivo Miracle**”), pursuant to which Blooming Faith has authorized Vivo Miracle to be the Singapore agent and dealer of the products and services sold by Blooming Faith.

AUTHORIZATION OF THE SALES AGENCY

1. Blooming Faith authorized Vivo Miracle to be the Singapore agent and dealer of nutritional supplements which includes ZJ1 VC tablets, NMN series products, medical check-up projects, and membership sales services of the World Life Sciences Healthcare Association (the “**Product and Services**”).
2. Vivo Miracle’s exclusive dealership in Singapore will be for a period of one year from the date of signing the Agency Contract. Upon expiry of the exclusive dealership, Vivo Miracle shall be given priority to negotiate with Blooming Faith for the extension of the exclusive dealership in Singapore and Blooming Faith shall negotiate and sign a supplemental agreement with Vivo Miracle based on Vivo Miracle’s sales performance.

3. For the subsequent launch of future products and services, Blooming Faith will give priority consideration to authorizing Vivo Miracle as an agent and negotiating a supplemental agreement.

DURATION OF THE SALES AGENCY

The Agency Contract is for an initial period of three years commencing from the date of signing of the Agency Contract. Blooming Faith and Vivo Miracle agreed that Vivo Miracle should achieve a minimum HK\$20,000,000 on Products and Services (including referral members and referral customers) in the first year from the date of signing the contract, with annual increments of 15% thereafter. Blooming Faith reserves the right to downgrade Vivo Miracle's agency status if Vivo Miracle does not complete its annual Product and Services spending. If Vivo Miracle achieves the target spending for three years from the date of signing the contract, the Agency Contract will be automatically extended for another three years; if the target spending is not achieved, the Agency Contract of Vivo Miracle will be automatically cancelled.

PAYMENT

Vivo Miracle shall pay Blooming Faith HK\$5,000,000 for the purchase of Products and Services within three working days of the Agency Contract taking effect.

INFORMATION ABOUT VIVO MIRACLE

Vivo Miracle is a company incorporated in Hong Kong and an advanced biotechnology company primarily engaged in the provision of consulting and sales services in advanced medical testing, technology applications, biologics and nutritional supplements, with Singapore and Asia as its major markets. The company has more than ten partner medical institutions in Singapore, providing high-end advanced medical services to its clients. Its chief executive officer, Ms. He Yuting, has 15 years of experience in sales of related products and has multiple local sales teams under her management.

REASONS FOR AND BENEFITS OF THE AGENCY CONTRACT

The Board believes that the Agency Contract will further improve the Group's global footprint in longevity science, and further enhance its leading position in the longevity medicine industry chain, which will bring stable and sustainable revenue growth to the Group in the long run.

By order of the Board
Zhong Ji Longevity Science Group Limited
Yan Li
Chairman

Hong Kong, 9 September 2021

As at the date of this announcement, the Directors are:

Executive Directors

Mr. Yan Li (*Chairman*)
Mr. Wang Hongxin (*Chief Executive Officer*)
Mr. Li Xiaoshuang
Ms. Cao Xie Qiong

Independent non-executive Directors

Mr. Tam Ho Leung Simon
Ms. Wang Weixia
Mr. Chai Nan

Non-executive Directors

Dr. He Yiwu
Ms. Choi Ngai Wah

In the case of any inconsistency, the English text of this announcement shall prevail over the Chinese text.